Inherited disposition to cardiac myxoma development

Nature Reviews Cancer

Volumn 6, Issue 2, 2006, Pages 157-165

  Wilkes, David ^a   Charitakis, Konstantinos ^a   Basson, Craig T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN;

BLUE NEVUS; CAFE AU LAIT SPOT; CARCINOGENESIS; CARNEY COMPLEX; CHROMOSOME 17; CLINICAL FEATURE; ENDOCRINE DISEASE; GENE; GENE MUTATION; GENETIC ENGINEERING; HEART MYXOMA; HEART TUMOR; HUMAN; HYPOPHYSIS ADENOMA; INHERITANCE; LENTIGO; LINKAGE ANALYSIS; MISSENSE MUTATION; MYXOMA; NONHUMAN; PATHOGENESIS; PPKAR1A GENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; SKIN TUMOR; THYROID TUMOR; TRICHOEPITHELIOMA;

ANIMALS; CELL PROLIFERATION; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; ENDOCRINE SYSTEM DISEASES; GENETIC PREDISPOSITION TO DISEASE; HEART NEOPLASMS; HUMANS; MICE; MYXOMA; PROTEINS; SIGNAL TRANSDUCTION; SKIN PIGMENTATION; SYNDROME;

EID: 33644846508     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1798     Document Type: Review

References (109)

1. Kendall, D. & Symonds, B. Epileptiform attacks due to myxoma of the right auricle. Br. Heart J. 14, 139-143 (1952).
2. Frankenfeld, R. H., Waters, C. H. & Steiner, R. C. Bilateral myxomas of the heart. Ann. Intern. Med. 53, 827-838 (1960).
3. Atherton, D. J., Pitcher, D. W., Wells, R. S. & MacDonald, D. M. A syndrome of various cutaneous pigmented lesions, myxoid neurofibromata and atrial myxoma: the NAME syndrome. Br. J. Dermatol. 103, 421-429 (1980).
4. Rees, J. R., Ross, F. G. M. & Keen, G. Lentiginosis and left atrial myxoma. Brit Heart J. 35, 874-876 (1973).
5. Koopman, R. J. & Happle, R. Autosomal dominant transmission of the NAME syndrome (nevi, atrial myxoma, mucinosis of the skin and endocrine overactivity). Hum. Genet. 86, 300-304 (1991).
6. Carney, J. A., Gordon, H., Carpenter, P. C., Shenoy, B. V. & Go, V. L. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine 64, 270-283 (1985). Elegant clinical description of the syndrome that bears the eponym Carney complex.
7. Vidaillet, H. J. Jr, Seward, J. B., Fyke, F. E. 3rd, Su, W. P. & Tajik, A. J. 'Syndrome myxoma': a subset of patients with cardiac myxoma associated with pigmented skin lesions and peripheral and endocrine neoplasms. Br. Heart J. 57, 247-255 (1987).
8. Veugelers, M. et al. Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. Proc. Natl Acad. Sci. USA 101, 14222-14227 (2004). Comprehensive survey of PRKAR1A mutations in CNC and description of the histological, biochemical and genetic features of a genetically engineered mouse model of CNC.
9. Veugelers, M. et al. Mutation of perinatal myosin heavy chain associated with a Carney complex variant. N. Engl. J. Med. 351, 460-469 (2004). Describes the identification of a gene that is responsible for trismus-pseudocamptodactyly syndrome and a variant form of CNC that includes trismus-pseudocamptodactyly.
10. Burke, A. & Virmani, R. in Atlas of Tumor Pathology. Third Series. Fascicle 16. (Washington, DC: Armed Forces Institute of Pathology, 1996).
11. Burke, A. P. et al. in World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart (eds Travis, W. D. et al.) 260-265 (IARC Press, Lyon, 2004).
12. Reynen, K. Cardiac myxomas. N. Engl. J. Med. 333, 1610-1617 (1995).
13. Ferrans, V. J. & Roberts, W. C. Structural features of cardiac myxomas: histology, histchemistry and electron microscopy. Hum. Pathol. 4, 111-146 (1973).
14. Lie, J. T. The identity and histogenesis of cardiac myxomas: a controversy put to rest. Arch. Pathol. Lab. 113, 724-726 (1989).
15. Basson, C. T. & Aretz, H. T. A 27-year-old woman with two intracardiac masses and a history of endocrinopathy. N. Engl. J. Med. 346, 1152-1158 (2002).
16. McCarthy, P. M. et al. The significance of multiple, recurrent, and 'complex' cardiac myxomas. J. Thorac. Cardiovasc. Surg. 91, 389-396 (1986).
17. Stratakis, C. A., Kirschner, L. S. & Carney, J. A. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J. Clin. Endocrinol. Metab. 86, 4041-4046 (2001).
18. Carney, J. A., Headington, J. T. & Su, W. P. Cutaneous myxomas. A major component of the complex of myxomas, spotty pigmentation, and endocrine overactivity. Arch. Dermatol. 122, 790-798 (1986).
19. Bennett, K. R. et al. The Carney complex: unusual skin findings and recurrent cardiac myxoma. Arch. Dermatol. 141, 916-918 (2005).
20. Kennedy, R. H., Waller, R. R. & Carney, J. A. Ocular pigmented spots and eyelid myxomas. Am. J. Ophthal. 104, 533-538 (1987).
21. Schweizer-Cagianut, M., Salomon, F. & Hedinger, C. E. Primary adrenocortical nodular dysplasia with Cushing's syndrome and cardiac myxomas: a peculiar familial disease. Virchows. Arch. Path. Anat. 397, 183-192 (1982).
22. Kurtkaya-Yapicier, O. et al. Pituitary adenoma in Carney complex: an immunohistochemical, ultrastructural, and immunoelectron microscopic study. Ultrastruct. Pathol. 26, 345-353 (2002).
23. Stratakis, C. A. et al. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex) J. Clin. Endocrinol. Metab. 82, 2037-2043 (1997).
24. Radin, R. & Kempf, R. A. Carney complex: report of three cases. Radiology 196, 383-386 (1995).
25. Premkumar, A., Stratakis, C. A., Shawker, T. H., Papanicolaou, D. A. & Chrousos, G. P. Testicular ultrasound in Carney complex: report of three cases. J. Clin. Ultrasound. 25, 211-214 (1997).
26. Utiger, C. A. & Headington, J. T. Psammomatous melanotic schwannoma: a new cutaneous marker for Carney's complex. Arch. Dermatol. 129, 202-204 (1993).
27. Claessens, N. et al. Cutaneous psammomatous melanotic schwannoma: non-recurrence with surgical excision. Am. J. Clin. Dermatol. 4, 799-802 (2003).
28. Carney, J. A. & Toorkey, B. C. Myxoid fibroadenoma and allied conditions (myxomatosis) of the breast. A heritable disorder with special associations including cardiac and cutaneous myxomas. Am. J. Surg. Pathol. 15, 713-721 (1991).
29. Carney, J. A. & Toorkey, B. C. Ductal adenoma of the breast with tubular features. A probable component of the complex of myxomas, spotty pigmentation, endocrine overactivity, and schwannomas. Am. J. Surg. Pathol. 15, 722-731 (1991).
30. Stratakis, C. A. et al. Ovarian lesions in Carney complex: clinical genetics and possible predisposition to malignancy. J. Clin. Endocrinol. Metab. 85, 4359-4366 (2000).
31. Barlow, J. F. et al. Myxoid tumor of the uterus and right atrial myxomas. S. D. J. Med. 36, 9-13 (1983).
32. Stratakis, C. A. et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J. Clin. Invest. 97, 699-705 (1996). Survey of clinical features of CNC and a potential CNC locus on chromosome 2, although several families that were subsequently described were shown to be associated with PRKAR1A defects on chromosome 17 (see references 33-35).
33. Casey, M. et al. Identification of a novel genetic locus for familial cardiac myxomas and Carney complex. Circulation 98, 2560-2566 (1998). Demonstration that the most important gene defect that causes CNC is associated with chromosome 17.
34. Casey, M. et al. Mutations in the protein kinase A R1α regulatory subunit cause familial cardiac myxomas and Carney complex. J. Clin. Invest. 106, R31-R38 (2000). Initial published report that mutations in the PRKAR1A gene cause CNC.
35. Kirschner, L. S. et al. Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex. Nature Genet. 26, 89-92 (2000). Identification of mutations in the PRKAR1A gene that cause CNC.
36. Boshart, M., Weih, F., Nichols, M. & Schutz, G. The tissue-specific extinguisher locus TSE1 encodes a regulatory subunit of cAMP-dependent protein kinase. Cell 66, 849-859 (1991).
37. Jones, K. W., Shapero, M. H., Chevrette, M. & Fournier, R. E. Subtractive hybridization cloning of a tissue-specific extinguisher: TSE1 encodes a regulatory subunit of protein kinase A. Cell 66, 861-872 (1991).
38. McKnight, G. S. et al. Analysis of the cAMP-dependent protein kinase system using molecular genetic approaches. Recent Prog. Horm. Res. 44, 307-335 (1988).
39. Beebe, S. J. & Corbin, J. D. Rat adipose tissue cAMP-dependent protein kinase: a unique form of type II. Mol. Cell. Endocrinol. 36, 67-78 (1984).
40. Scott, J. D. Cyclic nucleotide-dependent protein kinases. Pharmacol. Ther. 50, 123-145 (1991).
41. Taylor, S. S., Buechler, J. A. & Yonemoto, W. cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Ann. Rev. Biochem. 59, 971-1005 (1990). Review of PKA structure and function.
42. Kirschner, L. S. et al. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Hum. Mol. Genet. 9, 3037-3046 (2000). Survey of PRKAR1A mutations in CNC and illustration of NMD of mutant alleles.
43. Gibson, R. M., Ji-Buechler, Y. & Taylor, S. S. Interaction of the regulatory and catalytic subunits of the cAMP-dependent protein kinase. Electrostatic sites on the type Iα regulatory subunit. J. Biol. Chem. 272, 16343-16350 (1997).
44. Gibson, R. M. & Taylor, S. S. Dissecting the cooperative reassociation of the regulatory and catalytic subunits of cAMP-dependent protein kinase. Role of Trp-196 in the catalytic subunit. J. Biol. Chem. 272, 31998-32005 (1997).
45. Groussin, L. et al. Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. Am. J. Hum. Genet. 71, 1433-1442 (2002).
46. Perlick, H. A., Medghalchi, S. M., Spencer, F. A., Kendzior, R. J. Jr & Dietz, H. C. Mammalian orthologues of a yeast regulator of nonsense transcript stability. Proc. Natl Acad. Sci. USA 93, 10928-10932 (1996).
47. Frischmeyer, P. A. & Dietz, H. C. Nonsense-mediated mRNA decay in health and disease. Hum. Mol. Genet. 8, 1893-1900 (1999).
48. Mabuchi, T. et al. PRKAR1A gene mutation in patients with cardiac myxoma. Int. J. Cardiol. 102, 273-277 (2005).
49. Stratakis, C. A. Mutations of the gene encoding the protein kinase A type I-α regulatory subunit (PRKAR1A) in patients with the 'complex of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas' (Carney complex). Ann. NY Acad. Sci. 968, 3-21 (2002).
50. Taymans, S. E., Kirschner, L. S., Giatzakis, C. & Stratakis, C. A. Characterization of the adrenal gland pathology of Carney complex, and molecular genetics of the disease. Endocr. Res. 24, 863-864 (1998).
51. Irvine, A. D. et al. Evidence for a second genetic locus in Carney complex. Br. J. Dermatol. 139, 572-576 (1998).
52. Maldonado, F. & Hanks, S. K. A cDNA clone encoding human cAMP-dependent protein kinase catalytic subunit Cα. Nucleic Acids Res. 16, 8189-8190 (1988).
53. Beebe, S. J. et al. Molecular cloning of a tissue-specific protein kinase (Cγ) from human testis - representing a third isoform for the catalytic subunit of cAMP-dependent protein kinase. Mol. Endocrinol. 4, 465-475 (1990).
54. Tasken, K. et al. The gene encoding the catalytic subunit C-α of cAMP-dependent protein kinase (locus PRKACA) localizes to human chromosome region 19p13.1. Genomics 36, 535-538 (1996).
55. Berube, D. et al. Assignment of the gene encoding the catalytic subunit Cβ of cAMP-dependent protein kinase to the p36 band on chromosome 1. Cytogenet. Cell. Genet. 58, 1850 (1991).
56. Boshart, M., Weih, F., Nichols, M. & Schutz, G. The tissue-specific extinguisher locus TSE1 encodes a regulatory subunit of cAMP-dependent protein kinase. Cell 66, 849-859 (1991).
57. Tasken, K., Naylor, S. L., Solberg, R. & Jahnsen, T. Mapping of the gene encoding the regulatory subunit RII-α of cAMP-dependent protein kinase (locus PRKAR2A) to human chromosome region 3p21.3-p21.2. Genomics 50, 378-381 (1998).
58. Solberg, R. et al. Mapping of the regulatory subunits RI-β and RII-β of cAMP-dependent protein kinase genes on human chromosome 7. Genomics 14, 63-69 (1992).
59. Skalhegg, B. S. & Tasken, K. Specificity in the cAMP-PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA. Front. Biosci. 5, D678-D693 (2000).
60. Corbin, J. D., Keely, S. L. & Park, C. R. The distribution and dissociation of cyclic adenosine 3′:5′-monophosphate-dependent protein kinases in adipose, cardiac, and other tissues. J. Biol. Chem. 250, 218-225 (1975).
61. Clegg, C. H., Cadd, G. G. & McKnight, G. S. Genetic characterization of a brainspecific form of the type I regulatory subunit of cAMP-dependent protein kinase. Proc. Natl Acad. Sci. USA 85, 3703-3707 (1988).
62. Wong, W. & Scott, J. D. AKAP signalling complexes: focal points in space and time. Nature Rev. Mol. Cell Biol. 5, 959-970 (2004).
63. Feliciello, A., Gottesman, M. E. & Awedimento, E. V. The biological functions of A-kinase anchor proteins. J. Mol. Biol. 308, 99-114 (2001).
64. Rubin, C. S. A kinase anchor proteins and the intracellular targeting of signals carried by cyclic AMP. Biochim. Biophys. Acta. 1224, 467-479 (1994).
65. Imaizumi-Scherrer, T., Faust, D. M., Barradeau, S., Hellio, R. & Weiss, M. C. Type I protein kinase a is localized to interphase microtubules and strongly associated with the mitotic spindle. Exp. Cell Res. 264, 250-265 (2001).
66. Coghlan, V. M., Bergeson, S. E., Langeberg, L., Nilaver, G. & Scott, J. D. A-kinase anchoring proteins: a key to selective activation of cAMP-responsive events? Mol. Cell. Biochem. 127-128, 309-319 (1993).
67. Lin, R. Y., Moss, S. B. & Rubin, C. S. Characterization of S-AKAP84, a novel developmentally regulated A kinase anchor protein of male germ cells. J. Biol. Chem. 270, 27804-27811 (1995).
68. Trendelenburg, G., Hummel, M., Riecken, E. O. & Hanski, C. Molecular characterization of AKAP149, a novel A kinase anchor protein with a KH domain. Biochem. Biophys. Res. Commun. 225, 313-319 (1996).
69. Huang, L. J., Durick, K., Weiner, J. A., Chun, J. & Taylor, S. S. D-AKAP2, a novel protein kinase A anchoring protein with a putative RGS domain. Proc. Natl Acad. Sci. USA 94, 11184-11189 (1997).
70. Wang, L. et al. Cloning and mitochondrial localization of full-length D-AKAP2, a protein kinase A anchoring protein. Proc. Natl Acad. Sci. USA 98, 3220-3225 (2001).
71. Alto, N., Carlisle Michel, J. J., Dodge, K. L., Langeberg, L. K. & Scott, J. D. Intracellular targeting of protein kinases and phosphatases. Diabetes 51 (Suppl.), S385-S388 (2002).
72. Perkins, G. A. et al. PKA, PKC, and AKAP localization in and around the neuromuscular junction. BMC Neurosci. 2, 17 (2001).
73. Lester, L. B. & Scott, J. D. Anchoring and scaffold proteins for kinases and phosphatases. Recent. Prog. Horm. Res. 52, 409-429 (1997).
74. Fan, G., Shumay, E., Wang, H. & Malbon, C. C. The scaffold protein gravin (cAMP-dependent protein kinase-anchoring protein 250) binds the β2-adrenergic receptor via the receptor cytoplasmic Arg-329 to Leu-413 domain and provides a mobile scaffold during desensitization. J. Biol. Chem. 276, 24005-24014 (2001).
75. Skalhegg, B. S. et al. Mutation of the Cα subunit of PKA leads to growth retardation and sperm dysfunction. Mol. Endocrinol. 16, 630-639 (2002).
76. Brandon, E. P. et al. Hippocampal long-term depression and depotentiation are defective in mice carrying a targeted disruption of the gene encoding the RIβ subunit of cAMP-dependent protein kinase. Proc. Natl Acad. Sci. USA. 92, 8851-8855 (1995).
77. Cummings, D. E. et al. Genetically lean mice result from targeted disruption of the RIIβ subunit of protein kinase A. Nature 382, 622-626 (1996).
78. Burton, K. A., Treash-Osio, B., Muller, C. H., Dunphy, E. L. & McKnight, G. S. Deletion of type IIα regulatory subunit delocalizes protein kinase A in mouse sperm without affecting motility or fertilization. J. Biol. Chem. 274, 24131-24136 (1999).
79. Rao, Y. et al. Reduced ocular dominance plasticity and long-term potentiation in the developing visual cortex of protein kinase A RIIα mutant mice. Eur. J. Neurosci. 20, 837-842 (2004).
80. Amieux, P. S. et al. Increased basal cAMP-dependent protein kinase activity inhibits the formation of mesoderm-derived structures in the developing mouse embryo. J. Biol. Chem. 277, 27294-27304 (2002). Initial description of a Prkar1a-null mouse that demonstrates the key role of Prkar1a in early embryogenesis.
81. Bertherat, J. et al. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res. 63, 5308-5319 (2003).
82. Tsilou, E. T. et al. Eyelid myxoma in Carney complex without PRKAR1A allelic loss. Am. J. Med. Genet. 130, 395-397 (2004).
83. Seizinger, B. R. et al. Report of the committee on chromosome and gene loss in neoplasia. Cytogenet. Cell Genet. 58, 1080-1096 (1991).
84. Molnar, J., Weiss, J. S. & Rosenthal, J. E. Does heart rate identify sudden death survivors? Assessment of heart rate, QT interval, and heart rate variability. Am. J. Ther. 9, 99-110 (2002).
85. Guzzetti, S. et al. Different spectral components of 24h heart rate variability are related to different modes of death in chronic heart failure. Eur. Heart J. 26, 357-362 (2005).
86. Villareal, R. P., Liu, B. C. & Massumi, A. Heart rate variability and cardiovascular mortality. Curr. Atheroscler. Rep. 4, 120-127 (2002).
87. Griffin, K. J. et al. A mouse model for Carney complex. Endocr. Res. 30, 903-911 (2004).
88. Kirschner, L. S. et al. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res. 65, 4506-4514 (2005).
89. Groussin, L. et al. Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease. J. Clin. Endocrinol. Metab. 87, 4324-4329 (2002).
90. Rosenberg, D. et al. Role of the PKA-regulated transcription factor CREB in development and tumorigenesis of endocrine tissues. Ann. NY Acad. Sci. 968, 65-74 (2002).
91. Ghosh, S. & Baltimore, D. Activation in vitro of NF-κB by phosphorylation of its inhibitor IκB. Nature 344, 678-682 (1990).
92. Collins, S. P., Reoma, J. L., Gamm, D. M. & Uhler, M. D. LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. Biochem. J. 345, 673-680 (2000).
93. Lania, A. G. et al. Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase a regulatory subunit 1A protein. Cancer Res. 64, 9193-9198 (2004).
94. Gordge, P. C., Hulme, M. J., Clegg, R. A. & Miller, W. R. Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. Eur. J. Cancer 32A, 2120-2126 (1996).
95. Bradbury, A. W. et al. Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa. Br. J. Cancer 69, 738-742 (1994).
96. McDaid, H. M. et al. Increased expression of the RIα subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. Br. J. Cancer 79, 933-939 (1999).
97. Fossberg, T. M., Doskeland, S. O. & Ueland, P. M. Protein kinases in human renal cell carcinoma and renal cortex. A comparison of isozyme distribution and of responsive ness to adenosine 3′:5′-cyclic monophosphate. Arch. Biochem. Biophys. 189, 272-281 (1978).
98. Nakajima, F., Imashuku, S., Wilimas, J., Champion, J. E. & Green, A. A. Distribution and properties of type I and type II binding proteins in the cyclic adenosine 3′:5′-monophosphate-dependent protein kinase system in Wilms' tumor. Cancer Res. 44, 5182-5187 (1984).
99. Miller, W. R., Elton, R. A., Dixon, J. M., Chetty, U. & Watson, D. M. Cyclic AMP binding proteins and prognosis in breast cancer. Br. J. Cancer 61, 263-266 (1990).
100. Miller, W. R., Watson, D. M., Jack, W., Chetty, U. & Elton, R. A. Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Res. Treat. 26, 89-94 (1993).
101. Simpson, B. J. et al. Cyclic adenosine 3′,5′-monophosphate- binding proteins in human ovarian cancer: correlations with clinicopathological features. Clin. Cancer Res. 2, 201-206 (1996).
102. Nesterova, M. & Cho-Chung, Y. S. A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth. Nature Med. 1, 528-533 (1995).
103. Cho-Chung, Y. S., Pepe, S., Clair, T., Budillon, A. & Nesterova, M. cAMP-dependent protein kinase: role in normal and malignant growth. Crit. Rev. Oncol. Hematol. 21, 33-61 (1995).
104. Cho-Chung, Y. S. et al. Antisense DNA-targeting protein kinase A-RIA subunit: a novel approach to cancer treatment. Front. Biosci. 4, D898-D907 (1999). Review of therapeutic applications for manipulation of R1α signalling in malignant tumours.
105. Farrow, B. et al. Inhibition of pancreatic cancer cell growth and induction of apoptosis with novel therapies directed against protein kinase A. Surgery 134, 197-205 (2003).
106. Tortora, G. & Ciardiello, F. Targeting of epidermal growth factor receptor and protein kinase A: molecular basis and therapeutic applications. Ann. Oncol. 11, 777-783 (2000).
107. Nesterova, M. & Cho-Chung, Y. S. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIα subunit. Antisense Nucleic Acid Drug Dev. 10, 423-433 (2000).
108. Cho, Y. S. et al. Protein kinase A RIα antisense inhibition of PC3M prostate cancer cell growth: Bcl-2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation. Clin. Cancer Res. 8, 607-614 (2002).
109. Wang, H. et al. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration. Proc. Natl Acad. Sci. USA 96, 13989-13994 (1999).